2026-04-13T13:30:16Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/1739122025-12-05T13:17:26Zcom_2072_1057col_2072_478798col_2072_478916col_2072_478917
RECERCAT author Møller, Pål author Seppälä, Toni T. author Bernstein, Inge author Holinski Feder, Elke author Sala, Paulo author Evans, D. Gareth author Lindblom, Annika author Macrae, Finlay author Blanco Guillermo, Ignacio author Sijmons, Rolf H. author Jeffries, Jacqueline author Vasen, Hans author Burn, John author Nakken, Sigve author Hovig, Eivind author Rødland, Einar Andreas author Tharmaratnam, Kukatharmini author de Vos Tot Nederveen Cappel, Wouter H. author Hill, James author Wijnen, Juul T. author Jenkins, Mark A. author Green, Kate author Lalloo, Fiona author Sunde, Lone author Mints, Miriam author Bertario, Lucio author Pineda Riu, Marta author Navarro García, Matilde author Morak, Monika author Renkonen Sinisalo, Laura author Frayling, Ian M. author Plazzer, John-Paul author Pylvänäinen, Kirsi author Genuardi, Maurizio author Mecklin, Jukka-Pekka author Möslein, Gabriela author Sampson, Julian R. author Capellá, G. (Gabriel) author Mallorca Group 2021-02-12T09:35:07Z2021-02-12T09:35:07Z2017-092021-02-12T09:35:07Z Objective Today most patients with Lynch syndrome (LS) survive their first cancer. There is limited information on the incidences and outcome of subsequent cancers. The present study addresses three questions: (i) what is the cumulative incidence of a subsequent cancer; (ii) in which organs do subsequent cancers occur; and (iii) what is the survival following these cancers? Design Information was collated on prospectively organised surveillance and prospectively observed outcomes in patients with LS who had cancer prior to inclusion and analysed by age, gender and genetic variants. Results 1273 patients with LS from 10 countries were followed up for 7753 observation years. 318 patients (25.7%) developed 341 first subsequent cancers, including colorectal (n=147, 43%), upper GI, pancreas or bile duct (n=37, 11%) and urinary tract (n=32, 10%). The cumulative incidences for any subsequent cancer from age 40 to age 70 years were 73% for pathogenic MLH1 (path_MLH1), 76% for path_MSH2 carriers and 52% for path_MSH6 carriers, and for colorectal cancer (CRC) the cumulative incidences were 46%, 48% and 23%, respectively. Crude survival after any subsequent cancer was 82% (95% CI 76% to 87%) and 10-year crude survival after CRC was 91% (95% CI 83% to 95%). Conclusions Relative incidence of subsequent cancer compared with incidence of first cancer was slightly but insignificantly higher than cancer incidence in patients with LS without previous cancer (range 0.94-1.49). The favourable survival after subsequent cancers validated continued follow-up to prevent death from cancer. The interactive website http://lscarisk.org was expanded to calculate the risks by gender, genetic variant and age for subsequent cancer for any patient with LS with previous cancer. cc by-nc (c) Møller, Pal et al., 2017 http://creativecommons.org/licenses/by-nc/3.0/es/ info:eu-repo/semantics/openAccess Càncer Supervivència Factors de risc en les malalties Cancer Survival Risk factors in diseases Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion